palbociclib

Known as: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one 
An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent… (More)
National Institutes of Health

Related topics

Related topics

14 relations

Broader (4)

Antineoplastic AgentsPiperazinesProtein Kinase InhibitorsPyridines
Cyclin-Dependent KinasesGene Expression RegulationKinase Inhibitors [MoA]Negative Regulation of G1 Phase
(More)

Narrower (1)

PD 0332991

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle regulation would contribute to promising… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Palbociclib and Letrozole in Advanced Breast Cancer.
BACKGROUND A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3…
BACKGROUND In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2016
Review
2016
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Cyclins and cyclin-dependent protein kinases (CDKs) are important regulatory components that are required for cell cycle… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
To the Editor: In the PALOMA3 study, Turner et al. (July 16 issue)1 report that the addition of palbociclib to fulvestrant… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
PURPOSE The G1-S checkpoint of the cell cycle is frequently dysregulated in breast cancer. Palbociclib (PD0332991) is an oral… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Review
2015
Review
2015
Palbociclib: First Global Approval
Palbociclib (Ibrance®) is an oral, reversible, selective, small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and CDK6… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.
n engl j med 373;17 nejm.org october 22, 2015 1673 and we will be updating efficacy and safety data. The first updated data… (More)
  • figure 1
Is this relevant?
Review
2015
Review
2015
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
On February 3, 2015, the FDA granted accelerated approval to palbociclib (IBRANCE, Pfizer Inc.), an inhibitor of cyclin-dependent… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast…
BACKGROUND Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with… (More)
Is this relevant?